Silk Road Medical Inc Revenue Growth Rates (SILK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Silk Road Medical Inc   (NASDAQ: SILK)
 

SILK's Revenue Growth by Quarter and Year

Silk Road Medical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SILK Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 50.51
1st Quarter March 47.50
FY 98.01

SILKs Annual Revenue
Silk Road Medical Inc 's Revenue in the fiscal year 2023 $ 177.09 millions
Silk Road Medical Inc 's Revenue in the fiscal year 2022 $ 138.64 millions
Silk Road Medical Inc 's Revenue in the fiscal year 2021 $ 101.48 millions
Silk Road Medical Inc 's Revenue in the fiscal year 2020 $ 75.23 millions
Silk Road Medical Inc 's Revenue in the fiscal year 2019 $ 63.35 millions




SILK Revenue second quarter 2024 Y/Y Growth Comment
Silk Road Medical Inc reported Revenue increase of 11.52% year on year in the second quarter 2024, to $ 50.51 millions, this is lower than Silk Road Medical Inc 's recent average Revenue improvement of 39.85%.

Looking into second quarter 2024 results within Medical Equipment & Supplies industry 74 other companies have achieved higher Revenue growth. While Silk Road Medical Inc ' s Revenue growth of 11.52% ranks overall at the positon no. 1248 in the second quarter 2024.


SILK Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 17.99 % 41.74 % 33.79 %
3rd Quarter September - 18.79 % 51.3 % 23.07 %
2nd Quarter June 11.52 % 36.54 % 25.36 % 75.35 %
1st Quarter March 18.37 % 43.22 % 27.07 % 16.48 %
FY   - 27.74 % 36.61 % -

Financial Statements
Silk Road Medical Inc 's second quarter 2024 Revenue $ 50.51 millions SILK's Income Statement
Silk Road Medical Inc 's second quarter 2023 Revenue $ 45.29 millions Quarterly SILK's Income Statement


SILK Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 6.51 % 7.23 % 14.45 %
3rd Quarter September - -1.99 % 12.66 % -6.65 %
2nd Quarter June 6.33 % 12.86 % 18.38 % 20 %
1st Quarter March 0.47 % 0.15 % -0.88 % 4.35 %
FY (Year on Year)   - 27.74 % 36.61 % -


Back to SILK Growth rate Comparisons >> Back to SILK Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #289
Overall #1248

Revenue Y/Y Growth Statistics
High Average Low
123.73 % 39.85 % 1.11 %
(Jun 30 2021)   (Jun 30 2020)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #75
Healthcare Sector #289
Overall #1248
Revenue Y/Y Growth Statistics
High Average Low
123.73 % 39.85 % 1.11 %
(Jun 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Silk Road Medical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
36.12 % 9.77 % -20.28 %
(Jun 30 2018)  


SILK's II. Quarter Q/Q Revenue Comment
Silk Road Medical Inc achieved in the II. Quarter 2024 below company average Revenue increase of 6.33% quarter on quarter, to $ 50.51 millions.

Within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue quarter on quarter growth. While Silk Road Medical Inc 's Revenue growth quarter on quarter, overall rank is 1619.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #340
Overall #1619
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #340
Overall #1619
Revenue Q/Q Growth Statistics
High Average Low
36.12 % 9.77 % -20.28 %
(Jun 30 2018)  


SILK's II. Quarter Q/Q Revenue Comment
Silk Road Medical Inc achieved in the II. Quarter 2024 below company average Revenue increase of 6.33% quarter on quarter, to $ 50.51 millions.

Within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue quarter on quarter growth. While Silk Road Medical Inc 's Revenue growth quarter on quarter, overall rank is 1619.


Silk Road Medical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 189.67 $ 184.46 $ 177.09 $ 169.88 $ 162.87
Y / Y Revenue Growth (TTM) 16.45 % 22.36 % 27.73 % 33.94 % 42.67 %
Year on Year Revenue Growth Overall Ranking # 317 # 168 # 198 # 507 # 429
Seqeuential Revenue Change (TTM) 2.83 % 4.16 % 4.24 % 4.3 % 8.04 %
Seq. Revenue Growth (TTM) Overall Ranking # 1293 # 791 # 831 # 1285 # 1496


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2024 period, Silk Road Medical Inc 's cumulative twelve months Revenue were $ 190 millions, company would post below average annual Revenue growth of 8.04% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Silk Road Medical Inc 's Revenue growth from the 47.5% growth in Mar 31 2024.

In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 168 to 317.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 87
Healthcare Sector # 111
Overall # 317

Revenue TTM Y/Y Growth Statistics
High Average Low
42.67 %
 31.97 %
16.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 272
S&P 500 # 1293
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2024 period, Silk Road Medical Inc 's cumulative twelve months Revenue were $ 190 millions, company would post below average annual Revenue growth of 16.45% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Silk Road Medical Inc 's Revenue growth from the 47.5% growth in Mar 31 2024.

In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 168 to 317.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 87
Healthcare Sector # 111
Overall # 317

Revenue TTM Y/Y Growth Statistics
High Average Low
42.67 %
31.97 %
16.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 272
S&P 500 # 1293




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SILK's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Amgen Inc 20.07%$ 20.069 millions
Si bone inc 19.97%$ 19.975 millions
United Therapeutics Corporation19.85%$ 19.849 millions
Neuropace Inc 19.80%$ 19.797 millions
Irhythm Holdings Inc 19.68%$ 19.676 millions
Biomarin Pharmaceutical Inc19.61%$ 19.613 millions
Ionis Pharmaceuticals Inc 19.55%$ 19.552 millions
Cadre Holdings inc 19.51%$ 19.514 millions
Novocure Limited19.28%$ 19.282 millions
Paragon 28 inc 19.11%$ 19.106 millions
Aim Immunotech Inc 19.05%$ 19.048 millions
Ani Pharmaceuticals Inc18.44%$ 18.441 millions
Glaukos Corp18.33%$ 18.335 millions
Vivos Therapeutics Inc 17.85%$ 17.850 millions
Procyon Corporation17.51%$ 17.513 millions
Bausch and Lomb Corp17.49%$ 17.488 millions
Bruker Corporation17.48%$ 17.476 millions
American Shared Hospital Services17.22%$ 17.216 millions
Amneal Pharmaceuticals Inc 17.15%$ 17.154 millions
Qhslab Inc 16.87%$ 16.875 millions
Cerus Corporation16.51%$ 16.506 millions
Veracyte Inc 16.15%$ 16.154 millions
Curis Inc 15.89%$ 15.885 millions
Scorpius Holdings inc 15.53%$ 15.532 millions
Mangoceuticals Inc 15.52%$ 15.524 millions
Integrated Biopharma Inc15.35%$ 15.352 millions
Maxcyte inc 15.33%$ 15.332 millions
Myriad Genetics Inc 15.26%$ 15.259 millions
P3 Health Partners Inc 15.22%$ 15.215 millions
Dexcom Inc 15.20%$ 15.196 millions


About Silk Road Medical Inc Revenue Growth Rates (SILK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Silk Road Medical Inc (CIK 1397702).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001397702-24-000049
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Silk Road Medical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.